Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids

Reiss, Theodore F.; Sorkness, Christine A.; Stricker, William; Botto, Albert; Busse, William W.; Kundu, Sudeep; Ji Zhang
January 1997
Thorax;Jan1997, Vol. 52 Issue 1, p45
Academic Journal
No abstract available.


Related Articles

  • Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. Lofdahl, Claes-Goran // BMJ: British Medical Journal (International Edition);07/10/99, Vol. 319 Issue 7202, p87 

    Presents information on a study on the ability of montelukast, a leukotriene receptor antagonist, to allow tapering of inhaled corticosteroids in clinically stable asthmatic patients. Participants and methods; Results; Conclusions.

  • Montelukast and Dosage of Inhaled Steroids in Asthma. Walling, Anne D. // American Family Physician;11/15/1999, Vol. 60 Issue 8, p2374 

    Presents an abstract of the study `Randomised, Placebo-controlled Trial of Effect of a Leukotriene Receptor Antagonist, Montelukast, on Tapering Inhaled Corticosteroids in Asthmatic Patients,' by C.G. Lofdahl et al., which appeared on July 10, 1999 issue of the `British Medical Journal.'

  • Effect of Montelukast Treatment on Serum Paraoxonase Activity in Asthmatic Children. Can, Murat; Mungan, A. Görkem; Açikgöz, Şerefden; Yüksel, Birol; Demırtaş, Selda; Tomaç, Nazan // Turkish Journal of Medical Sciences;2007, Vol. 37 Issue 6, p373 

    Montelukast, widely used in the treatment of asthma, is a selective and potent oral cysteinyl leukotriene-1 receptor antagonist. In this study, we investigated the effects of montelukast on oxidative stress and antioxidant defense in childhood asthma by measuring malondialdehyde and the...

  • Update on the use of montelukast in pediatric asthma. Capristo, Carlo; Rigotti, Erika; Boner, Attilio L. // Allergy & Asthma Proceedings;Jul/Aug2006, Vol. 27 Issue 4, p312 

    Cysteinyl leukotrienes are inflammatory bioactive lipids produced by various cells. They are present in increased amounts in airway secretions of all different asthma phenotypes and can induce all the inflammatory changes observed in the airways of asthmatic patients. For this reason, an attempt...

  • RoIe of cysteinyl leukotrienes in adenosine 5' -monophosphate induced bronchoconstriction in asthma. Rorke, S.; Jennison, S.; Jeffs, J. A.; Sampson, A. P.; Arshad, H.; Holgate, S. T. // Thorax;Apr2002, Vol. 57 Issue 4, p323 

    Background: Adenosine induced bronchoconstriction in patients with asthma is thought to be mediated by the synthesis and release of autacoids from airway mast cells. In vitro, adenosine induced constriction of asthmatic bronchi is blocked by a combination of specific histamine and cysteinyl...

  • Structure based virtual screening of ligands to identify cysteinyl leukotriene receptor 1 antagonist. Bandaru, Srinivas; Marri, Vijaya Kumar; Kasera, Priyadarshani; Kovuri, Purnima; Girdhar, Amandeep; Mittal, Deepti Raj; Ikram, Sabeen; Ravi, G. V.; Nayarisseri, Anuraj // Bioinformation;2014, Vol. 10 Issue 10, p652 

    Montelukast and Zafirlukast are known leukotriene receptor antagonists prescribed in asthma treatment. However, these fall short as mono therapy and are frequently used in combination with inhaled glucocorticosteroids with or without long acting beta 2 agonists. Therefore, it is of interest to...

  • How effective are leukotriene inhibitors for asthma in children? Morden, Nancy E.; St. Anna, Leilani // Journal of Family Practice;Apr2004, Vol. 53 Issue 4, p325 

    explains that leukotrienes are potent mediators of inflammation and are believed to contribute significantly to the inflammatory pathophysiology of asthma. Leukotriene inhibitors interfere with leukotriene production or leukotriene receptors and thus inhibit inflammation. For children, the...

  • Churg–Strauss syndrome (CSS) in a patient receiving pranlukast. Kobayashi, Shigeto; Ishizuka, Shyugo; Tamura, Naoto; Takaya, Makiyo; Kaneda, Kazuhiko; Hashimoto, Hiroshi // Clinical Rheumatology;Dec2003, Vol. 22 Issue 6, p491 

    Pranlukast is a cysteinyl leukotriene receptor I antagonist (LTRAs) approved for treatment of asthma in Japan since 1995. Compared to other LTRAs, such as zafilukast and montelukast, only few cases with Churg-Strauss syndrome (CSS) have been reported in association with treatment with...

  • leukotriene-receptor antagonist (Major drug group).  // Royal Society of Medicine: Medicines;2002, p329 

    The article presents information on leukotriene-receptor antagonist. Drugs work as anti-allergic agents by blocking the actions of leukotrienes, which are natural inflammatory mediators released in most tissues and organs including the lungs. Montelukast is used in anti-asthmatic treatment as a...

  • Benefit-Risk Assessment of Antileukotrienes in the Management of Asthma. García-Marcos, Luis; Schuster, Antje; Pérez-Yarza, Eduardo G. // Drug Safety;May2003, Vol. 26 Issue 7, p483 

    Antileukotrienes are a relatively new class of anti-asthma drugs that either block leukotriene synthesis (5-lipoxygenase inhibitors) like zileuton, or antagonise the most relevant of their receptors (the cysteinyl leukotriene 1 receptor [CysLT1]) like montelukast, zafirlukast or pranlukast....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics